Publications

Detailed Information

Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial : Sacituzumab govitecan in HR<SUP>+</SUP>HER2<SUP>-</SUP> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial

DC Field Value Language
dc.contributor.authorXu, Binghe-
dc.contributor.authorWang, Shusen-
dc.contributor.authorYan, Min-
dc.contributor.authorSohn, Joohyuk-
dc.contributor.authorLi, Wei-
dc.contributor.authorTang, Jinhai-
dc.contributor.authorWang, Xiaojia-
dc.contributor.authorWang, Ying-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorJiang, Dongdong-
dc.contributor.authorValdez, Theresa-
dc.contributor.authorDasgupta, Anandaroop-
dc.contributor.authorZhang, Yiran-
dc.contributor.authorYan, Yilin-
dc.contributor.authorKomatsubara, Kimberly M.-
dc.contributor.authorChung, Wei-Pang-
dc.contributor.authorMa, Fei-
dc.contributor.authorDai, Ming-Shen-
dc.date.accessioned2024-12-11T06:49:12Z-
dc.date.available2024-12-11T06:49:12Z-
dc.date.created2024-12-11-
dc.date.created2024-12-11-
dc.date.created2024-12-11-
dc.date.created2024-12-11-
dc.date.issued2024-12-
dc.identifier.citationNature Medicine, Vol.30 No.12, pp.3709-3716-
dc.identifier.issn1078-8956-
dc.identifier.urihttps://hdl.handle.net/10371/213589-
dc.description.abstractSacituzumab govitecan (SG) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR(+)HER2(-)) metastatic breast cancer (mBC) in the global TROPiCS-02 study. TROPiCS-02 enrolled few Asian patients. Here we report results of SG in Asian patients with HR(+)HER2(-) mBC from the EVER-132-002 study. Patients were randomized to SG (n = 166) or chemotherapy (n = 165). The primary endpoint was met: PFS was improved with SG versus chemotherapy (hazard ratio of 0.67, 95% confidence interval 0.52-0.87; P = 0.0028; median 4.3 versus 4.2 months). OS also improved with SG versus chemotherapy (hazard ratio of 0.64, 95% confidence interval 0.47-0.88; P = 0.0061; median 21.0 versus 15.3 months). The most common grade >= 3 treatment-emergent adverse events were neutropenia, leukopenia and anemia. SG demonstrated significant and clinically meaningful improvement in PFS and OS versus chemotherapy, with a manageable safety profile consistent with prior studies. SG represents a promising treatment option for Asian patients with HR(+)HER2(-) mBC (ClinicalTrials.gov identifier no. NCT04639986).-
dc.language영어-
dc.publisherNature Publishing Group-
dc.titleSacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial-
dc.title.alternativeSacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial-
dc.typeArticle-
dc.identifier.doi10.1038/s41591-024-03269-z-
dc.citation.journaltitleNature Medicine-
dc.identifier.wosid001326615500001-
dc.identifier.scopusid2-s2.0-85205513353-
dc.citation.endpage3716-
dc.citation.number12-
dc.citation.startpage3709-
dc.citation.volume30-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusANTIBODY-DRUG CONJUGATE-
dc.subject.keywordPlusOPEN-LABEL-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share